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Introduction: Imatinib, a tyrosine kinase inhibitor, is a major therapeutic option for the management of unresectable
aggressive fibromatosis. Unfortunately, for most patients of low or very low average income countries, surgery often is
the first treatment option. This is related to unavailability of chemotherapy or targeted therapy, and to a lack of
financial resources or surgeons’ lack of knowledge of other therapeutic options.
Case presentation: In 2010, a 26-year-old Moroccan man was referred to our oncology and radiotherapy center
by his surgeon for the management of a recurrent tumor of his right subscapularis muscle. Before his assessment
in our center, two resections were performed by his surgeon after performing an incision biopsy and magnetic
resonance imaging. Postoperative magnetic resonance imaging was performed and showed a right axillary
nodule size 2.1cm regarding a collection with a residual tumor. We decided to administer imatinib 400mg daily
by mouth. Clinical and magnetic resonance imaging evaluation were performed regularly and reported a stable
tumor. We reported no adverse side effects to imatinib regarding Common Terminology Criteria for Adverse
Events grading.
Conclusions: Recurrences are high during aggressive fibromatosis management. Systemic treatment with
imatinib for unresectable or recurrent tumors with positive c-KIT could be the best therapeutic option. In our
case report, the patient was stabilized with imatinib for 30 months and he had a very good quality of life.
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Imatinib, a tyrosine kinase inhibitor, is a major therapeutic
option for the management of unresectable aggressive
fibromatosis (AF) or desmoid tumors [1]. These tumors
are non-malignant and aggressive; they can occur any-
where in the body. Extra-abdominal forms are usually
confined to the musculature and the overlying aponeur-
osis or fascia but the neoplasm may infiltrate the
surrounding tissue up to 2 to 3cm outside the palpable
tumor [2]. Management of these tumors is not standard-
ized but relies on the combination of surgery, radiotherapy
and/or systemic therapy. Local control is the main goal
of treatment and there has been a change in the* Correspondence: daocl@yahoo.fr
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unless otherwise stated.management of these tumors from aggressive surgical
resection to function preservation [3]. The surgical
resection rate regarding primary treatment modality
for desmoid tumors when functionally and cosmetic-
ally acceptable with reported local control is 75 to 80%
[3]. For surgery alone, local recurrence rates varied
from 24 to 77% which justified the use of other therapeutic
options. Systemic therapy has been reported regarding
cytotoxic agents [4] but with documented cardiotoxicity
and myelosuppression. Regarding the relative toxicities of
cytotoxic agents, hormonal therapy and tyrosine kinase
inhibitors are increasingly reported as therapeutic options
[5]. Imatinib mesylate (Gleevec®) is a specific tyrosine
kinase inhibitor highly used for targeting c-KIT, breakpoint
cluster region-abelson gene (BCR-ABL), platelet-derivedis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Dao et al. Journal of Medical Case Reports 2014, 8:416 Page 2 of 5
http://www.jmedicalcasereports.com/content/8/1/416growth factor receptors (PDGFRs) and macrophage
colony-stimulating factor receptor. Longtime disease
stabilization with imatinib mesylate has been reported
in different series of patients with relapsing desmoid
tumors, with 1-year progression-free survival rates close
to 60 to 70% [6-8]. Unfortunately, for most patients of low
or very low average income countries, surgery often is the
first treatment option. This is related to the unavailability
of chemotherapy or targeted therapy, and a lack of finan-
cial resources or lack of surgeons’ knowledge of other
therapeutic options. Although AF tumors are benign, the
best management of AF is a multidisciplinary approach to
plan local control with acceptable morbidity.
Case presentation
In 2010, a 26-year-old Moroccan man was referred to
our oncology and radiotherapy center for management
of recurrent tumor of his right subscapularis. No
pathological medical or surgical history was reported
and no alcohol or tobacco habits. One year before, he
had presented to his surgeon with a subscapularis tumor
which had appeared gradually and increased in size duringFigure 1 Images of the first recurrence. Thoracic computed tomograph
imaging with axial (C) and sagittal (D) cut showing mass measuring 130mm
and chest wall, hypointensity T1, hypersignal T2; this mass displaces the m6 months without associated pain or other symptoms. A
physical examination reported a mass size 10cm, palpated
in his right subscapularis region. A first resection was
realized. Histopathological analysis demonstrated spindle-
shaped cells with no identifiable nuclear pleomorphism or
mitotic activity. There was no necrosis. A benign tumor
with spindle-shaped cells is suspected. On immunohis-
tochemical analysis, the cells stained positive for anti-
smooth muscle actin, favoring a smooth muscle origin.
The diagnostic of AF was retained. Unfortunately, the
mass recurred within a period of 10 months and contin-
ued to increase in size reaching 13cm on a computed
tomography scan and magnetic resonance imaging (MRI;
Figure 1) without regional structures involved (bone,
muscle or vascular). A second tumor and lymph nodes re-
section were performed by another surgeon who reported
“a very hard resection without cleavage plane”. Histo-
logical analysis regarding two fragments size 4×3cm and
14×10×8cm led to a conclusion of AF tumor; hormonal
receptor was not found. The resections of margins were
narrowed and lymph node resections regarding four nodes
were not involved. At assessment in our oncology andy axial cut (A) and sagittal cut (B). Auxiliary magnetic resonance
. This mass was localized on the right chest wall, between scapula
uscle structures; auxiliary vessels are permeable.
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Health Organization performance status was zero, weight
84kg, height 177cm. There was no induration or palpable
mass. A MRI performed after the repeat surgery was
normal. During follow up, a recurrence was suspected 1
year after the second resection. An axillary MRI (Figure 2A
and 2B) was performed and a large mass was found in the
last tumor site, measuring 12.6cm involving deltoid mus-
cles and extending to axillary area. A third resection was
realized and a histopathological examination showed the
same AF tumor with a low positivity of c-KIT. Margins
were narrowed. Post-surgery MRI (Figure 2C and 2D) was
performed and showed a right axillary residual tumor
measuring 2.1cm. Diagnosis of recurrent AF tumor with
positive c-KIT and without hormonal receptor was
retained. The decision to administrate imatinib 400mg
daily by mouth was taken. His follow up was performed
by clinical examination and was normal during 6 months.
When we stopped imatinib administration during 1
month, the tumor grew to a size of 4cm. RetreatmentFigure 2 Pre and post second surgery magnetic resonance imaging. A
(A-B) and after surgery (C-D). Magnetic resonance imaging axial and sagitt
on high axis in right chest wall, hypointensity T1 and hyperintensity T2, conta
remains permeable and are not involved; a second similar soft tissue mass of
noted. After surgery, right auxiliary magnetic resonance imaging (C-D) was pewith imatinib was decided. Clinical and MRI evaluation
were performed regularly and they reported a stable
tumor. The last MRI (Figure 3A) was performed in
January 2014; it showed a stabilized tumor and many
intratumoral calcifications. We reported no side effects
regarding Common Terminology Criteria for Adverse
Events. Currently he is feeling well but he continues to
have ankylosis (90°) in his right upper limb due to the
particular localization of AF and surgery (Figure 3B).
Discussion
In low average income countries like Morocco, according
to gross national income of World Bank Atlas 2008, tar-
geted therapies are not always accessible to all patients.
For this case report we presented to our patient the ad-
vantages and disadvantages of imatinib versus iterated sur-
geries. During management of our case report, despite
major surgery, two recurrences were reported within 12
months which justified the introduction of imatinib. In
the subscapularis region, which is an unusual localizationxillary magnetic resonance imaging performed before second surgery
al cut (A-B) showing soft-tissue mass recurrences measuring 126mm
ct with axillary pedicle and brachial vessels homolateral. These vessels
right chest wall in posterior areas measuring 61mm in diameter was
rformed and showed a residual tumor measuring 21mm.
Figure 3 Last magnetic resonance imaging and patient status.
Axillary magnetic resonance imaging (A) showing tumor and many
intratumoral calcifications. (B) Patient with limited right upper
member abduction to 90°.
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were almost involved or narrow despite the surgeon’s
experience. Thus, the patient took imatinib during 2.5
years and he was stabilized with a good quality of life. Our
patient received 400mg orally daily. The daily dose of ima-
tinib was controversial in the literature. Some authors
started with a standard dose [9], other authors started
with a low dose and raised it after 2 weeks [10], and an-
other author started with a high dose and decreased the
dose when side effects occurred [7]. We reported no side
effects within this case report. Imatinib is well tolerated in
published series and only side effects of grade I/II tired-
ness and edema were reported without any major effects
(grade III/IV) [7].
Mace et al. resumed the pharmaceuticals action of
imatinib mesylate (Gleevec™; Novartis Pharmaceuticals,
Hanover, NJ, USA) as a selective tyrosine kinase inhibi-
tor targeting Bcr-Abl fusion protein in chronic myeloge-
nous leukemia, multiple class 3 receptor tyrosine kinases
including PDGFR-α and PDGFR-β, as well as the c-KIT
subtype [7].
This agent blocks ligand-activated receptor phosphor-
ylation and mitogen-activated kinase activation and pro-
liferation, resulting in the inhibition of cellular growth
and proliferation. Complete or even partial responsesare documented in the literature in approximately 10 to
23% of patients treated with imatinib. Our patient has
been treated with imatinib for 24 months. The mean
follow-up time in the literature varied from 12 to 19.7
months [7,11]. However, not all clinical studies have
been entirely positive regarding the use of imatinib. The
French sarcoma group, in a SARC trial, demonstrated
positive initial results of nonprogression rates at 3 and 6
months of 90% and 80%, respectively, but these decreased
at 12 months to 67%. The median time to progression was
25 months in this study [6]. These results were confirmed
in the SARC trial with initial progression-free survival of
94% and 88% at 1- and 2-months follow-up appointments
but these decreased significantly to 66% at 1 year [12]. A
2012 review [13] reported the increasing interest in the
potential role for tyrosine kinase inhibitors in the treat-
ment of extra-abdominal desmoid tumors despite a lim-
ited role for imatinib alone but recommended it as part of
therapeutic options. Sunitinib, another tyrosine kinase in-
hibitor, could be useful in some cases of AF, especially if
there is resistance to imatinib [11]. Other systemic therap-
ies, including nonsteroidal anti-inflammatory drugs such
as indomethacin and sulindac, and tranilast, were used
without randomized trials.
Conclusions
The aggressiveness of desmoid tumors is related to their
frequent recurrences despite surgical resection with clear
margins. Surgery of tumors located in the subscapularis
is almost R1 (resection is narrowed or involved micro-
scopically) and recurrences or progression are evident.
Systemic treatment with imatinib for unresectable or
recurrent tumors with positive c-KIT could be the best
therapeutic option. In our case report, the patient was
stabilized with imatinib for 30 months and had a very
good quality of life.
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